Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers
نویسندگان
چکیده
منابع مشابه
Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers
PURPOSE Traditional chemotherapy is the main adjuvant therapy for the treatment of non-small cell lung cancer (NSCLC). However, the emergence of multi-drug resistance (MDR) has greatly restricted the curative effect of chemotherapy. Therefore, it is necessary to find a method to treat MDR NSCLC clinically. It is worth investigating whether NSCLCs that are resistant to traditional chemotherapy c...
متن کاملPolymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers
BACKGROUND The epidermal growth factor receptor (EGFR) gene is the prototype member of the type I receptor tyrosine kinase (TK) family and plays a pivotal role in cell proliferation and differentiation. There are three well described polymorphisms that are associated with increased protein production in experimental systems: a polymorphic dinucleotide repeat (CA simple sequence repeat 1 [CA-SSR...
متن کاملEGFR mutations in non-small-cell lung cancer.
The epidermal growth factor receptor (EGFR) family members seem to play a critical role in lung tumourigenesis and are overexpressed in 40-80% of non-small cell lung carcinoma (NSCLC) tumours. EGFR activation results in a series of downstream signaling events that mediate cancer cell growth, proliferation, motility, adhesion, invasion, apoptosis inhibition and metastasis as well as resistance t...
متن کاملPostoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
BACKGROUND The aim of this retrospective study is to identify epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer patients and to compare the long-term postoperative outcomes in different EGFR-TKI-targeted therapy effects between the different EGFR mutation groups. METHODS A total of 2094 postoperative non-small cell lung cancer (NSCLC) patients with EGFR gene dete...
متن کاملEGFR mutations in exons 18-21 in sporadic breast cancer.
The epidermal growth factor receptor (EGFR) is implicated in breast cancer (BC) progression and is associated with an aggressive phenotype. The presence of EGFR mutations in exons 18–21 in BC, as in non-small-cell lung cancer [1], might help predict patient response to EGFR inhibitors such as erlotinib and gefitinib. The EGFR mutation rate in patients with BC is still poorly defined. We analyse...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Yonsei Medical Journal
سال: 2016
ISSN: 0513-5796,1976-2437
DOI: 10.3349/ymj.2016.57.1.50